公开(公告)号：EP0888456B1

公开(公告)日：2006-05-31

申请号：EP97916850.7

申请日：1997-03-19

申请人： THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES

发明人： SCHLOM, Jeffrey ,  TSANG, Kwong-yok ,  ZAREMBA, Sam

IPC分类号： C12N15/57 ,  C12N9/64 ,  A61K38/48 ,  C12N5/10 ,  C12N7/01 ,  A61K39/00

CPC分类号： A61K39/0011 ,  A61K38/00 ,  A61K39/00 ,  A61K2035/124 ,  A61K2039/5154 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/53 ,  A61K2039/55522 ,  A61K2039/55527 ,  C12N5/0636 ,  C12N9/6445 ,  C12N2710/24143 ,  Y10S435/975

摘要： The invention is a prostate specific antigen oligo-epitope peptide which comprises more than one PSA epitope peptide, which conforms to one or more human HLA class I motifs. The prostate specific antigen oligo-epitope peptide in combination with various HLA-class I molecules or interactions with various T-cell receptors elicits PSA specific cellular immune responses. The prostate specific antigen oligo-epitope peptide is useful as an immunogen in the prevention or treatment of prostatic cancer, in the inhibition of prostatic cancer cells and in the establishment and characterization of PSA-specific cytotoxic T-cell lines.

公开(公告)号：EP0888456A2

公开(公告)日：1999-01-07

申请号：EP97916850.0

申请日：1997-03-19

申请人： THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES

发明人： SCHLOM, Jeffrey ,  TSANG, Kwong-yok ,  ZAREMBA, Sam

IPC分类号： A61K39 ,  C07H21 ,  C07K14 ,  C12N5 ,  C12N9 ,  C12N15 ,  C12Q1 ,  A61K35 ,  A61K38

CPC分类号： A61K39/0011 ,  A61K38/00 ,  A61K39/00 ,  A61K2035/124 ,  A61K2039/5154 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/53 ,  A61K2039/55522 ,  A61K2039/55527 ,  C12N5/0636 ,  C12N9/6445 ,  C12N2710/24143 ,  Y10S435/975

摘要： The invention is a prostate specific antigen oligo-epitope peptide which comprises more than one PSA epitope peptide, which conforms to one or more human HLA class I motifs. The prostate specific antigen oligo-epitope peptide in combination with various HLA-class I molecules or interactions with various T-cell receptors elicits PSA specific cellular immune responses. The prostate specific antigen oligo-epitope peptide is useful as an immunogen in the prevention or treatment of prostatic cancer, in the inhibition of prostatic cancer cells and in the establishment and characterization of PSA-specific cytotoxic T-cell lines.